Verona Pharma plc
Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist

Last updated:

Abstract:

The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl- )-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.

Status:
Grant
Type:

Utility

Filling date:

5 Jun 2017

Issue date:

12 Nov 2019